TransCode Therapeutics, Inc., a clinical-stage oncology company, announced on November 5, 2024, that it has been granted an extension by the Nasdaq Hearings Panel to regain compliance with Nasdaq Listing Rules. The extension was given to address issues related to the bid price, equity, and shareholder approval of transactions. The company faced potential delisting due to its failure to secure shareholder approval for a significant share issuance at a substantial discount on July 22, 2024. Alongside the extension, TransCode received a Public Reprimand Letter. The company, which specializes in RNA therapeutics for cancer treatment, is working towards meeting Nasdaq's compliance conditions. TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors, and the company is developing a portfolio of RNA therapeutic candidates.

TransCode Therapeutics, Inc., a clinical-stage oncology company, announced on November 5, 2024, that it has been granted an extension by the Nasdaq Hearings Panel to regain compliance with Nasdaq Listing Rules. The extension was given to address issues related to the bid price, equity, and shareholder approval of transactions. The company faced potential delisting due to its failure to secure shareholder approval for a significant share issuance at a substantial discount on July 22, 2024. Alongside the extension, TransCode received a Public Reprimand Letter. The company, which specializes in RNA therapeutics for cancer treatment, is working towards meeting Nasdaq's compliance conditions. TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors, and the company is developing a portfolio of RNA therapeutic candidates.